November 2012 | Oncology Live®

December 12, 2012

An interview with Jenny C. Chang, MB BChir, MD, who broke new ground in cancer research when she identified and patented a 493-gene signature for breast cancer.

December 04, 2012

For the past 10 years, Matthew J.C. Ellis, MB BChir, PhD, has focused his research on exploring the breast cancer genome in partnerships with academic and government-funded centers in the United States and the United Kingdom.

December 04, 2012

The clinical subtyping of breast cancer appears to be coming into a golden era as an increased understanding of subtyping promises to help advance treatments and outcomes for patients.

December 03, 2012

Although new therapies have revolutionized the management of certain hematologic malignancies during the past 15 years, clinical trials currently under way hold the potential to yield new targeted agents and better treatment strategies.

November 30, 2012

Researchers are continuing to investigate TKIs to help manage patients with CML who either do not respond to initial therapy or relapse after subsequent treatment.

November 28, 2012

The pace of discovery in breast cancer research has been brisk in the past year, leading not only to the approval of several new therapies but also to clinical trial results with the potential to change practice.

November 28, 2012

Despite the trend toward targeted therapies, cytotoxic drugs remain a mainstay of metastatic breast cancer treatment, and new therapies in that class are needed.

November 20, 2012

For Johns Hopkins' gastrointestinal cancer surgeon Mark D. Duncan, those who help his patients cope with their diagnosis and manage their often complex treatment and follow-up are critical members of the healthcare team.

November 20, 2012

An exploratory analysis of the phase III AURELIA trial demonstrated that adding bevacizumab (Avastin) to chemotherapy in patients with platinum-resistant ovarian cancer benefited patients across treatment cohorts.

November 20, 2012

A data safety monitoring board (DSMB) has found that a phase III study of pomalidomide, an oral immunomodulatory agent, met its primary endpoint by demonstrating a significant improvement in progression-free survival for patients with multiple myeloma (MM).

November 19, 2012

Interim data from a phase II clinical study of the dendritic cell vaccine CVac in patients with epithelial ovarian cancer showed promising signs of improving PFS compared with the observational standard of care.

November 19, 2012

Targeted antineoplastic therapy based on the presence of a well-defined molecular target should be recognized as a standard-of-care approach in an increasing number of clinical settings.